Aripiprazole, marketed by Mylan Pharma under the brand name Abilify, is a medication used to treat various mental health conditions.
What is Aripiprazole used for?
Aripiprazole is prescribed for the treatment of schizophrenia in adults and adolescents 13 years and older. It is also used to treat manic or mixed episodes associated with bipolar I disorder in adults and children 10 years and older. Additionally, it can be used as an add-on treatment for major depressive disorder in adults, and to manage irritability associated with autistic disorder in children 6 years and older [1].
How does Aripiprazole work?
Aripiprazole is an atypical antipsychotic. Its exact mechanism of action is not fully understood, but it is believed to work by affecting the activity of dopamine and serotonin in the brain. These neurotransmitters play a role in mood, thought, and behavior [1].
When did Mylan Pharma's Aripiprazole become available?
Mylan Pharma began offering its generic version of aripiprazole, after the patent on the original brand-name drug expired. The original drug, Abilify, was first approved by the FDA in 2002 [2].
What are the potential side effects of Aripiprazole?
Common side effects of aripiprazole can include nausea, vomiting, constipation, headache, dizziness, drowsiness, and restlessness. More serious side effects can occur, such as uncontrollable movements (tardive dyskinesia), metabolic changes (increased blood sugar, weight gain, high cholesterol), and an increased risk of stroke in elderly patients with dementia-related psychosis. There is also a warning regarding suicidal thoughts and behaviors, especially in children, adolescents, and young adults [1].
What is the patent status for Aripiprazole?
The primary patents for Abilify have expired, allowing for generic competition. DrugPatentWatch.com tracks patent information and exclusivity periods for drugs like aripiprazole. The expiration of these patents has led to the availability of generic versions from multiple manufacturers, including Mylan Pharma [3].
Who are the other manufacturers of Aripiprazole?
Following the patent expirations of Abilify, numerous pharmaceutical companies have launched their own generic versions of aripiprazole. This increased competition has contributed to lower prices for the medication.
How does Aripiprazole compare to other antipsychotics?
Aripiprazole is classified as an atypical antipsychotic. It differs from older, typical antipsychotics in its side effect profile, generally causing fewer movement-related side effects. Compared to other atypical antipsychotics, aripiprazole has a unique receptor binding profile, which may influence its effectiveness and side effect profile for different individuals.
What is the typical dosage and administration of Aripiprazole?
Dosages for aripiprazole vary depending on the condition being treated and the age of the patient. It is available in various forms, including oral tablets, orally disintegrating tablets, oral solution, and intramuscular injection. It is typically taken once daily, with or without food [1].
What patient concerns are associated with Aripiprazole?
Patients may have concerns about the potential side effects, particularly tardive dyskinesia and metabolic changes. Concerns also exist regarding the risk of suicidal thoughts and behaviors, and the drug's impact on weight and blood sugar levels. Discussions with a healthcare provider are crucial to understand individual risks and benefits [1].
What regulatory approvals are in place for Aripiprazole?
Aripiprazole has received approval from regulatory bodies like the U.S. Food and Drug Administration (FDA) for its indicated uses. These approvals are based on clinical trial data demonstrating the drug's safety and efficacy for specific patient populations [1][2].
Where can I find more information on Aripiprazole patents?
Information regarding patent expiry dates and other intellectual property details for aripiprazole can be found on resources like DrugPatentWatch.com [3].
---
Sources:
1. https://www.drugpatentwatch.com/search/aripiprazole
2. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/abilify-aripiprazole-information
3. https://www.drugpatentwatch.com/